United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027
Share
Why It Matters
United Therapeutics got permission to have the FDA review a new medicine for a serious lung disease, with a decision expected by June 2027. When a medicine gets this green light to be reviewed, it means the company cleared an important hurdle, but we won't know if it's approved until the FDA finishes checking it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.